-->

Tech Seeker (TS)

Abgenix Inc
Profile last edited on: 4/4/2022

Biopharmaceutical company: human therapeutic antibodies
TS Type
Small Corporation
Status
Acquired
Year Founded
1996
Last Involved Year
2013

Key People / Management

  William R Ringo -- President

  Yasuhisa A Aono -- Director, Business Develo

  Helen E Chadd -- Associate Director, Busin

  Gayle M Mills -- VP, Business Development

  Mark E Nevins -- Director, Busines Develop

  Linda J Nyari -- Attorney

Location Information

6701 Kaiser Drive
Fremont, CA 94555
   (510) 608-6500
   www.abgenix.com

Public Profile

In December 2005 Abgenix Inc was acquired by Amgen itself - albeit on small scale - an SBIR involved firm in its early days. Formed by Cell Genesys Inc. (Foster City, California) Abgenix was established to develop the company's human monoclonal antibodies for pharmaceutical products. Abgenix platform includes leading technologies and state-of-the-art manufacturing capabilities that enable the rapid generation, selection, and production of high affinity, fully human antibodies for a variety of disease targets. Management are leveraging our leadership position in human antibody technology to build a diversified product portfolio. Our fully integrated product development capabilities range from the generation/characterization of antibodies to full-scale production in our state-of-the-art manufacturing facility. Core to our discovery platform are XenoMouse® and XenoMaxTM—proprietary technologies used to generate large pools of fully human antibodies from which to choose appropriate candidates. Once candidates are selected, they can be advanced through clinical development and commercial-scale production via proprietary cell lines and versatile process development technologies, as we leverage our process sciences plant and flexible clinical- and commercial-scale manufacturing infrastructure to streamline scale-up and minimize risks associated with biologics manufacturing.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
107
Revenue
$0.0B
Public/Private
Publicly Traded
Stock Info
NASDAQ : ABGX
Received SBIR $$
Yes

SBIR firms in the news

There are no news available.